AHNAK2 has a reported association with cisplatin (CIS) and 5-fluorouracil (5-FU) resistance, with 5-FU being used in colon, oesophageal, gastric, pancreatic, and breast cancers through the inhibition of thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA. This evidence concerns the gene AHNAK2 and in situ carcinoma.